Alyeska Investment Group
EIDX

Alyeska Investment Group’s Eidos Therapeutics, Inc. Common Stock EIDX Stock Holding History

Alyeska Investment Group’s Portfolio EIDX Stock Details EIDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-14,200
Closed -$142K – 507
2018
Q3 		$142K Buy
+14,200
New +$233K ﹤0.01% 394

Other funds holding EIDX

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
FCMI
Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
BOTOTLSJU
Board of Trustees of The Leland Stanford Junior University Redwood City, California $849M AUM 55.45% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Alyeska Investment Group's EIDX Position: Q4 2018 in Review

Alyeska Investment Group sold out of Eidos Therapeutics, Inc. Common Stock (EIDX) in Q4 2018, closing a stake of 14,200 shares — an estimated $142K sold.

Alyeska Investment Group first reported a position in EIDX in Q3 2018 and held it in 1 quarter. The position peaked at $142K in Q3 2018. 60 funds tracked by Wall St. Rank hold EIDX as of Q4 2018.

  • Alyeska Investment Group reported no remaining Eidos Therapeutics, Inc. Common Stock position as of Q4 2018 after selling out during the quarter.
  • Alyeska Investment Group sold 14,200 Eidos Therapeutics, Inc. Common Stock shares in Q4 2018, an estimated $142K.
  • Alyeska Investment Group first reported a position in Eidos Therapeutics, Inc. Common Stock in Q3 2018 and held it in 1 quarter.
  • Alyeska Investment Group's Eidos Therapeutics, Inc. Common Stock position peaked at $142K in Q3 2018.
  • 60 funds tracked by Wall St. Rank held Eidos Therapeutics, Inc. Common Stock as of Q4 2018.

Based on Alyeska Investment Group's 13F filing for Q4 2018, filed 14 Feb 2019.